Basic mechanisms of Immunotherapy

Making it in a simple Lenguage

Dr. Ada G. Blidner

Institute of Biology and Experimental Medicine, Buenos Aires, Argentina

adablidner@gmail.com

Who, Where, When?



Innate and Adaptive Immune Response



Antigen presentation and Priming



Koichi, Nature Reviews, 2012

Huppa, Nature Reviews, 2003

Integrating the Immune Response



What are checkpoints good for?



CTLA-4



PD-1



PD-1 is expressed following **T** cel **activation**

PD-L1 is expressed in lymphoid and non-lymphoid tissues. PD-L2 mainly in APCs

PD-L1 is expressed on Endothelial cells, which inhibit T cell activity in SLO

PD-1 is expressed in Exhausted T cells

PD-1



PD-1/PD-L1 interaction inhibits TCR mediated T cell activation and Proliferation

T cell ON/OFF



How do Tumors take advantage of IC?



How do Tumors take advantage of IC?

EQUILIBRIUM PHASE



CTLA-4 blockade broadens T cell repertoire



Differences between CTLA-4 and PD-1 blockade



Ligand Concentration

Th1/Th17 responses correlate with good prognosis



Personalized Immunotherapy



Thanks!

Immunopathology Lab, Institute of Biology and Experimental Medicine-CONICET



Dr. Gabriel Rabinovich, Senior Investigator, Full Professor FCEyN-UBA



Mizutani Foundation Glýčoscience













Aultiple Scleros









